LakeShore Biopharma Co., Ltd (LSBCF) is a biopharmaceutical firm dedicated to the end-to-end process of bringing innovative medical solutions to market. Its primary focus lies in creating vaccines and advanced therapeutic biologics, specifically designed to combat infectious diseases and various forms of cancer. A cornerstone of its strategy is the proprietary PIKA immunomodulating technology platform. This innovative platform underpins the development of several key pipeline assets, including a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. LakeShore Biopharma maintains operations across an international footprint, with a presence in China, the United States, Singapore, the United Arab Emirates, and the Philippines. Established in 2002, the company was initially known as YS Biopharma Co., Ltd. It rebranded to LakeShore Biopharma Co., Ltd in May 2024. The company's corporate headquarters are located in Beijing, China.
